Adrenocortical Production Is Associated with Higher Levels of Luteinizing Hormone in Nonobese Women with Polycystic Ovary Syndrome

Table 1

Clinical and biochemical characteristics of all subjects.

	Control	PCOS non obese	PCOS obese
𝑛	18	16	21
Presence of amenorrhea	0%	25%*	33%^#
Age (years)	32.7±6.2	26.1±5.5^∗	30.4±6.9
BMI (Kg/m^2)	23.9±3.6	25.2±3.3	37.9±4.7^#§
Waist (cm)	81.6±8.0	86.1±11.0	114.4±13.8^#§
Waist-hip ratio	0.9±0.1	0.9±0.1	0.98±0.1^#§
LH (mIU/mL)	5.6±2.0	13.7±11.3^∗	6.9±3.6^§
FSH (mIU/mL)	7.2±1.4	6.1±1.3	5.2±1.2^#
Androstenedione (ng/mL)	1.7±0.8	3.3±1.9^∗	2.8±2.1
DHEA (ng/mL)	5.5±3.4	13.8±10.8^∗	7.8±8.3
DHEA-S (µg/dL)	119.4±61.7	192.9±67.9^∗	136.6±66.3^§
Total testosterone (ng/dL)	33.8±12.4	64.8±29.6^∗	62.0±40.6^#
SHBG (nmol/L)	59.1±24.8	37.1±20.7^∗	26.7±13.4^#
FAI	2.4±1.2	8.5±8.8^∗	10.0±9.0^#
Free testosterone (ng/dL)	0.5±0.2	1.3±0.9^∗	1.4±1.1^#
Bioavailable testosterone (ng/dL)	11.0±4.3	23.0±11.2	32.0±24.8^#
Fasting glucose (mg/dL)	90.6±9.4	91.9±11.3	92.7±8.9
Fasting insulin (µU/mL)	6.6±2.7	8.4±5.7	13.5±5.6^#§
HOMA-IR (µIU/mL)	1.5±0.6	2.0±1.5	3.1±1.4^#§
Basal cortisol (ng/dL)	1016.6±367.0	1473.0±539.1^∗	1011.4±512.8^§
Cortisol after DEX (ng/dL)	198.9±219.7	282.7±329.1	162.7±176.4
∆ cortisol (ng/dL)	817.7±406.7	1190.0±549.7	848.8±489.6
Cortisol supression (%)	−78.7±25.3	−80.8±20.7	−82.5±16.5

^∗𝑃<.05 PCOS non obese versus control.
^#𝑃<.05 PCOS obese versus control.
^§𝑃<.05 PCOS obese versus PCOS non obese.